Kazia Therapeutics (ASX:KZA) Trading Down 2%

Kazia Therapeutics Ltd (ASX:KZA) was down 2% during mid-day trading on Thursday . The stock traded as low as A$0.48 ($0.34) and last traded at A$0.48 ($0.34), approximately 19,564 shares were traded during mid-day trading. The stock had previously closed at A$0.49 ($0.35).

The company has a market capitalization of $29.84 million and a P/E ratio of -2.68. The firm’s fifty day simple moving average is A$0.44.

About Kazia Therapeutics (ASX:KZA)

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.

Recommended Story: Correction

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.